Compare ELTX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | TNYA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 178.5M |
| IPO Year | 2014 | 2021 |
| Metric | ELTX | TNYA |
|---|---|---|
| Price | $10.69 | $0.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $5.33 |
| AVG Volume (30 Days) | 134.1K | ★ 5.0M |
| Earning Date | 03-12-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,301,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,456.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.60 | $0.36 |
| 52 Week High | $14.93 | $2.35 |
| Indicator | ELTX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 49.04 | 45.00 |
| Support Level | $9.84 | $0.66 |
| Resistance Level | $11.12 | $0.70 |
| Average True Range (ATR) | 0.99 | 0.07 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 29.20 | 22.17 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.